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ABSTRACT
Chromosomal translocations are one of the hallmarks of acute myeloid leukemia 
(AML), often leading to gene fusions and expression of an oncofusion protein. Over 
recent years it has become clear that most of the AML associated oncofusion proteins 
molecularly adopt distinct mechanisms for inducing leukemogenesis. Still these unique 
molecular properties of the chimeric proteins converge and give rise to a common 
pathogenic molecular mechanism. In the present study we compared genome-wide 
DNA binding and transcriptome data associated with AML1-ETO, CBFB-MYH11 and 
PML-RARA oncofusion protein expression to identify unique and common features. 
Our analyses revealed targeting of oncofusion binding sites to RUNX1 and ETS-
factor occupied genomic regions. In addition, it revealed a highly comparable global 
histone acetylation pattern, similar expression of common target genes and related 
enrichment of several biological pathways critical for maintenance of AML, suggesting 
oncofusion proteins deregulate common gene programs despite their distinct binding 
signatures and mechanisms of action.
INTRODUCTION
Acute myeloid leukemia (AML) is a heterogeneous 
disease characterized by many genetic variations, including 
chromosomal translocations. AML is a progressive 
malignant disease and leads to deranged populations of red 
blood cells, platelets, and normal white blood cells in bone 
marrow. AML is the most common form of acute leukemia 
in adults, is more prevalent in ageing populations and is 
responsible for ~1% of cancer deaths worldwide [1, 2]. 
However, AML is a potentially curable disease, although 
only a minority of patients are cured with current therapies. 
A large fraction of AMLs is associated with non-random 
chromosomal translocations  [2, 3] that often result in gene 
rearrangement and expression of an oncofusion protein. 
Gene rearrangements are believed to provide crucial ground 
work for cell transformation and initiation of leukemia. 
Studies have shown that targeting or silencing of these fusion 
transcripts in-vitro leads to reversal of leukemogenesis, 
decreased proliferation and differentiation [4].
We and others have focused on unraveling 
molecular aspects of several oncofusion proteins 
associated with AML, such as AML1-ETO [5, 6, 7, 8], 
CBFB-MYH11 [9], PML-RARA [10, 11], and FUS-ERG 
[12]. The AML1-ETO, CBFB-MYH11, and PML-RARA 
oncofusion protein associated AML-subtypes each 
account for 5%-10% of all AML cases while FUS-ERG 
fusions are relatively rare (<1%). The core-binding factor 
(CBF) oncofusion proteins AML1-ETO and CBFB-
MYH11 result from t(8;21) and inv(16) chromosomal 
rearrangements, while t(15;17) results in expression of 
PML-RARA. Although these three fusion proteins are 
generally associated with good prognosis, still 25-58% 
of relapse incidences are reported in patients with CBF-
AMLs [13, 14, 15, 16, 17] and ~10% in patients with 
t(15;17) [18]. These relapses often cannot be effectively 
treated with current therapies [19].
Interestingly, genome-wide analysis revealed that 
molecularly AML1-ETO exhibits properties similar to 
PML-RARA. Both are believed to exert their functional 
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influence by recruiting repressor complexes containing 
histone deacetylases to genomic target sites, thereby 
altering normal chromatin architecture and gene 
expression [2, 6]. In contrast, genome-wide analysis of 
CBFB-MYH11, classically believed to be a repressor, has 
suggested it to be an activator of genes involved in the 
self-renewal pathway [9].
From the above it is clear that the advent of next 
generation sequencing has broadened the study of 
oncofusion proteins from single loci to a genome-wide 
scale. Together with large cohorts of gene expression 
data from AML patients that have become available 
[20, 21, 22], it now provides an opportunity to perform 
comparative-integrative analysis of these oncofusion 
proteins to identify exclusive and mutually shared 
structural and functional features. Here we compared 
the specific features of PML-RARA, AML1-ETO 
and CBFB-MYH11 in order to define the common 
mechanisms in which these proteins are involved in 
leukemogenesis.
RESULTS
AML1-ETO, CBFB-MYH11 and PML-RARA 
target the RUNX1/ETS gene program
To identify the common binding and gene 
program of oncofusion proteins associated with AML 
we used previously identified target regions of PML-
RARA in the t(15;17) NB4 cell line [10], AML1-ETO 
in the t(8;21) Kasumi-1 cell line [6] and CBFB-MYH11 
in the inv(16) ME-1 cell line [9] for further analysis 
(Figure 1A). This revealed that the two core binding 
factor-oncofusion proteins, AML1-ETO and CBFB-
MYH11 differ significantly in their genomic distribution 
(Figure 1B), with AML1-ETO preferentially targeting 
distal elements and CBFB-MYH11 mostly promoter 
bound. In contrast, PML-RARA, which does not 
represent a core binding factor is similar in its targeting 
as AML1-ETO, mostly locating to distal sites (Figure 
1B). In line, PML-RARA and AML1-ETO share more 
binding sites (~20%) as compared to CBFB-MYH11 
and AML1-ETO (~5%), and CBFB-MYH11 and PML-
RARA (~6%) (Figure 1C).
To investigate whether the fusion proteins target a 
common transcription factor network we performed motif 
enrichment analysis on their binding sites, using weight 
matrices of AML1/RUNX1, C/EBPA, the ETS factor 
SPI1, GATA and TAL1, all transcription factors reported 
to be mutated in acute leukemias [23]. This revealed 
significant enrichment for AML1/RUNX1, SPI1, and 
GATA motifs at all sites, while TAL1 is more specific 
for core binding factors and enrichment for C/EBPA 
motifs is comparatively reduced at all sites (Figure 2A). 
Previous studies have shown co-occupancy of RUNX1 
and the ETS factors FLI1/ERG at AML1-ETO and CBFB-
MYH11 binding sites [6, 9]. Here, our analysis suggests 
also enrichment for RUNX1 and ETS factors at binding 
sites of PML-RARA. Indeed, examining RUNX1 and 
FLI1 enrichment at PML-RARA oncofusion protein 
binding sites confirmed enrichment of both (Figure 1A, 
2B). Together these results suggest a role for RUNX1 and 
members of the ETS family in modulating oncofusion 
protein binding and a possible role in regulating gene 
expression as suggested in previous studies [6, 9].
Oncofusion proteins AML1-ETO, CBFB-MYH11 
and PML-RARA target similar biological 
pathways
Progression of leukemia is not a consequence 
of a single deregulated pathway but is believed to be 
a synergistic impact of a wide range of misregulated 
pathways including cell cycle, differentiation, signaling, 
apoptosis and self-renewal pathways [24, 25, 26]. To 
identify the target gene programs of the oncofusion 
proteins we assigned binding sites to nearest genes within 
a window of 25 kb for further analysis. This revealed that 
many target genes are shared between the three oncofusion 
proteins with AML1-ETO and PML-RARA sharing a 
maximum number of 1175 (~40%) genes (Figure 3A), in 
line with their higher overlap of binding sites. Examining 
all 3 oncofusion proteins revealed 352 (~11%) genes 
commonly targeted, suggesting that despite occupying 
different genomic regions (Figure 1B), still many of the 
same genes are targeted. Furthermore, on investigating 
the set of genes differentially expressed upon AML1-
ETO knockdown in t(8;21) cells [5] in inv(16) AML cells 
before and after knockdown of CBFB-MYH11 revealed 
differential expression of 45% of genes (Supplementary 
Figure 1A and Supplementary Table 1). These results 
suggest that a large fraction of the target genes is indeed 
shared between the oncofusion proteins and likely 
involved in regulation of leukemogenesis.
Interestingly, this common target gene set 
exhibits significant higher expression across all fusion 
protein expressing AML subtypes as compared to 
normal CD34+ cells (Figure 3B), but similar to CMP 
and GMP progenitor populations, suggesting these 
represent the differentiation stage in which the AMLs 
are blocked. Comparison with the unique target gene 
set for each oncofusion protein revealed increased 
expression of the common gene set in all three AMLs 
(Figure 3C). Functional annotation of the common and 
unique target gene set revealed involvement of genes 
in many pathways, including acute myeloid leukemia, 
apoptosis and the TGF-β signaling pathway. In addition, 
enrichment of identical pathways through distinct gene 
sets was observed (Figure 3D). Higher expression of the 
genes associated with these pathways (Figure 3B & 3C) 
can have different functional effects as exemplified by 
the apoptosis pathway, which is enriched by the common 
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as well as unique target gene set of all three oncofusion 
proteins (Figure 3D). As the apoptosis pathway contains 
both anti- (e.g. BCL2) as well as pro- (e.g. BID) 
-apoptotic genes [27] we examined expression of both 
sets revealing that generally anti-apoptotic genes are 
higher expressed in AML, but also in normal progenitors 
(Figure 3E). Increased expression of anti-apoptotic 
genes in AML is in line with the presence of the 
‘prevention of cell death’ hallmark of cancer [28] and 
decreased apoptosis in oncofusion protein expressing 
AML cells.
AML subtype specific expression of genes
Despite targeting a common gene program a 
subset of genes is controlled by only one of the three 
oncofusion proteins (Figure 3A), suggesting the 
presence of AML subtype specific gene signatures. 
To identify specific gene expression signatures for 
each subtype of AML we analyzed gene expression in 
primary AMLs expressing AML1-ETO, CBFB-MYH11 
and PML-RARA [20, 21]. This led to the identification 
of signature genes for the three subtypes, including 
Figure 1: Genome-wide binding features of oncofusion proteins. A. Overview of the SPI1 and SLC39A13 AML1-ETO, CBFB-
MYH11, PML-RARA, RUNX1 and FLI binding sites in Kasumi-1, ME-1 and NB4 cells. B. Distribution of the AML1-ETO, CBFB-
MYH11 and PML-RARA binding site locations relative to RefSeq genes. Locations of binding sites are divided in promoter (-500 bp to 
the transcription start site), exon, intron and intergenic (everything else). C. Left: Venn diagram representing the overlap of AML1-ETO, 
CBFB-MYH11 and PML-RARA binding sites in Kasumi-1, ME-1 and NB4 cells. Right: Heatmap displaying tag densities in unique and 
shared binding sites of AML1-ETO, CBFB-MYH11 and PML-RARA oncofusion proteins.
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POU4F1 and PRAME genes in t(8;21) translocation, 
VCAN and S100A12 in inv(16) and CTSG and PTGDS 
in t(15;17) AMLs. Comparing these data to more recent 
RNA-seq analysis [22] confirmed these observations 
(Figure 4), suggesting the identification of a stable AML 
subtype specific gene signature that potentially can be 
used as biomarker.
AML1-ETO, CBFB-MYH11 and PML-RARA 
oncofusion proteins alter the acetylome
Acetylation and deacetylation of histones catalyzed 
by histone acetyltransferases (HATs) and histone 
deacetylases (HDACs), respectively, are two of the 
several mechanisms controlling the complex process of 
transcription. HATs and HDACs play opposite roles in 
gene regulation by modulating chromatin structure and 
activity of certain transcription factors by differential 
acetylation [29].
In cancerous cells acetylation levels are believed 
to be imbalanced and influencing expression levels 
of tumor suppressor genes and proto-oncogenes. 
Hyper-acetylated promoters of proto-oncogenes are 
suggested to increase expression of these genes and 
turn them into oncogenes. In contrast, hypo-acetylation 
of promoters of tumor suppressor genes invariably 
silences them [30]. Deregulation of target genes by (de)
acetylation seems a common mechanism for oncofusion 
proteins. Originally only associated with recruitment 
of HDACs, the oncofusion proteins AML1-ETO, 
PML-RARA and CBFB-MYH11 have recently been 
associated both with HAT and HDAC protein complex 
binding to balance histone acetylation output [6, 9, 10, 
31, 32].
Here, we compared binding sites of the three 
oncofusion proteins for H3 acetylation (H3K9K14ac) 
enrichment and observed high levels of acetylation at 
CBFB-MYH11 binding sites as compared to AML1-ETO 
and PML-RARA (Figure 5A). This is likely related to 
the differences in mechanistic properties, with CBFB-
MYH11 mostly binding, and potentially stabilizing, active 
promoters while AML1-ETO and PML-RARA bind and 
stabilize inactive enhancers. Interestingly, on examining 
global acetylation of CBFB-MYH11 defined regions 
in t(8;21) and t(15;17) cells we observe similar levels 
of increased acetylation (Figure 5B), while vice versa, 
comparatively reduced levels of acetylation at PML-
RARA and AML1-ETO binding sites are also observed 
in inv(16) cells. Furthermore, acetylation levels at these 
oncofusion protein binding sites seem further reduced in 
normal CD34+ cells (Figure 5B, Supplementary Figure 
1B), suggesting a specific acetylation signature for these 
leukemic cell types. Together these results suggest that 
despite oncofusion protein binding to different genomic 
regions, the resulting acetylome is to a large extend 
similarly organized in these AML cells.
Figure 2: Oncofusion binding sites are demarcated by RUNX1 and members of the ETS factor family. A. Plot depicting 
percentages of AML1-ETO, CBFB-MYH11 and PML-RARA binding sites harboring consensus sequences of transcription factors. B. 
Heatmap displaying tag densities at AML1-ETO, CBFB-MYH11 and PML-RARA binding in Kasumi-1, ME-1 and NB4 cells, respectively.
Oncotarget12859www.impactjournals.com/oncotarget
Figure 3: Expression of oncofusion target genes. A. Venn diagram representing overlap between the target genes of AML1-ETO, 
CBFB-MYH11 and PML-RARA. B. Higher expression of common target genes of AML1-ETO, CBFB-MYH11 and PML-RARA is 
observed in t(8;21), inv(16) and t(15;17) AML sub-types as compared to normal CD34+ (*p-value <0.05). While the expression in other 
cell types (CMP and GMP) doesn’t exhibit a significant change in expression. C. Comparison of expression of he 10% highest expressed 
genes, the 10% lowest expressed genes, unique target and common target genes of AML1-ETO, CBFB-MYH11 and PML-RARA in 
t(8;21), inv(16) and t(15;17) AML subtypes. D. Heatmap displaying enrichment of biological pathways. The common, AML1-ETO, CBFB-
MYH11 and PML-RARA gene set enrich identical as well as distinct pathways, suggesting similar pathways are enriched from distinct 
gene sets. E. Expression of apoptotic and anti-apoptotic genes in t(8;21), inv(16), t(15;17), CD34+, CMP and GMP cells.
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Figure 4: AML signature gene identification. Heatmap displaying expression levels of signature genes for t(8;21), inv(16) and 
t(15;17) AML identified in two cohort studies [21, 22].
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DISCUSSION
Many breakpoints involved in specific chromosomal 
translocations have been cloned over the years. In most 
cases, however, the role of the chimeric oncofusion 
proteins in tumorigenesis has not been elucidated. In 
the case of AML, our analysis of PML-RARA, AML1-
ETO, and CBFB-MYH11 were among the first to report 
on the genome-wide actions of oncofusion proteins. 
These genome-wide studies focused on revealing various 
structural and functional aspects of the oncofusion 
proteins like composition of the protein complexes formed 
by oncofusion proteins, the effects on the epigenetic 
landscape, the enriched pathways and deregulated gene 
networks. None of these studies carried out an integrative 
comprehensive analysis on the genome-wide maps of 
different oncofusion proteins and identify unique and 
mutually shared features between them.
Despite the suggested differences between these 
oncofusion proteins, the data presented here reveals the 
binding sites of all three are demarcated by RUNX1 
and ETS factors indicating the existence of a common 
functional RUNX1/ETS-factor module that is targeted 
in oncofusion mediated leukemogenesis. Similarly, the 
commonly targeted genes by all three oncofusion proteins 
show higher expression patterns in AML-subtypes as 
compared to CD34+ cells and enrich biological pathways 
crucial for leukemogenesis. Amongst these pathways are 
several signaling modules which likely stimulate cell 
proliferation, such as the TGFB signaling pathway [33]. In 
addition, all are enriched for genes involved in regulation 
of apoptosis, in particular anti-apoptotic genes which are 
higher expressed to prevent cell death. Together these data 
indicate that the distinct molecular properties of these 
oncofusion proteins converge on common mechanisms to 
transform cells.
Although utilizing distinct mechanisms to regulate 
the local epigenetic environment, with AML1-ETO 
and PML-RARA suggested to reduce acetylation (and 
expression of genes) [5, 6, 10, 32] and CBFB-MYH11 
to increase acetylation [9], the overall acetylome 
of all oncofusion protein binding sites seems very 
similar (Figure 5B). Despite different epigenetic and 
transcriptional effects at an individual gene level, 
these results suggest that each oncofusion protein 
fixes cells in a common ‘average leukemic’ state, with 
similar pathways activated and repressed. We propose 
that the combined set of all oncofusion binding sites 
represents interdependent regions that need to be 
switched on/off during hematopoietic differentiation 
(Figure 6). Although AML1-ETO and PML-RARA on 
one side and CBFB-MYH11 on the other side modulate 
gene expression through distinct mechanisms, the 
interdependencies still results in common global profiles 
in this model. Either gene set ‘A’ can be increased, 
resulting due to interdependency in decreased activity 
of gene set ‘B’ and subsequent differentiation, or gene 
set ‘B’ can be decreased, which results in increased 
expression of gene set ‘A’ and a similar expression 
profile. We propose that oncofusion proteins use this 
Figure 5: Histone H3 acetylation at AML1-ETO, CBFB-MYH11 and PML-RARA binding sites. A. H3 acetylation profile 
at AML1-ETO binding sites in Kasumi-1, at CBFB-MYH11 binding sites in ME-1 and at PML-RARA binding sites in NB4 cells. B. 
Heatmap displaying tag densities of H3K9K14ac in unique and shared binding sites of AML1-ETO, CBFB-MYH11 and PML-RARA 
oncofusion proteins.
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interdependency to lock differentiation pathways. 
Blocking gene set ‘A’ from becoming activated (for 
example as is the proposed mechanism for AML1-ETO 
and PML-RARA) will simultaneously prevent decreased 
expression of gene set ‘B’ and will lock the cells in a 
progenitor state. Similarly, maintaining activity of gene 
set ‘B’ (as being proposed for CBFB-MYH11) will 
prevent increased expression of gene set ‘A’ and results 
in a similar block. This ‘gene set’ lock might be further 
strengthened by additional co-occurring mutations.
Together, the commonalities discussed in this study 
might present novel entry points for further treatment of 
AML patients with these translocations, for example by 
targeting the RUNX1/ETS-factor interaction, disruption 
of the associated complex, or use of specific compounds 
that target one of the common pathways altered by the 
fusion proteins, such as BCL2 inhibitors [34, 35] to block 
the activation of the anti-apoptosis program. Finally, 
the common acetylation signature present in these cells 
might be targeted by specific drugs. While HDACi’s 
would be an obvious choice [36], the general toxicity 
invoked by these hyper-acetylating compounds makes 
them less suitable [37]. Using the alternative strategy 
of blocking acetylation to induce hypoacetylation, for 
example by iBETs or HATi might prove to be a better 
strategy in the long run.
EXPERIMENTAL PROCEDURE
Chromatin immunoprecipitation (ChIP)
Cell line were cross-linked with 1% formaldehyde 
for 20 min at room temperature, quenched with 0.125 
M glycine and washed. Sonicated chromatin (Bioruptor, 
Diagenode, Liege, Belgium) was centrifuged at maximum 
speed for 10 min and then incubated with specific 
antibodies. Beads were washed sequentially with four 
different wash buffers and chromatin was eluted from 
the beads. Protein–DNA crosslinks were reversed, after 
which DNA was isolated and used for quantitative PCR or 
sequencing analysis.
Illumina high-throughput sequencing
End repair was performed using the precipitated 
DNA of ~6 million cells (3-4 pooled biological replicas) 
Figure 6: Proposed mechanism for expression deregulation by AML1-ETO, CBFB-MYH11 and PML-RARA. The 
AML1-ETO and PML-RARA on one side and CBFB-MYH11 on the other side modulate gene expression using different mechanisms, 
but genes are interdependent. A gene set ‘A’ cannot be activated when a gene set ‘B’ is repressed and vice versa. By blocking activation of 
gene set ‘A’ reduced expression of gene set ‘B’ will be prevented and cells will be locked in a progenitor state (proposed for AML1-ETO 
and PML-RARA). A similar block can be created for gene set ‘A’ by maintaining activity of gene set ‘B’ (proposed for CBFB-MYH11).
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using Klenow and T4 polynucleotide kinase (T4 
PNK). A 3’ protruding A base was generated using Taq 
polymerase and adapters were ligated. The DNA was 
loaded on gel and a band corresponding to ~300 bp 
(ChIP fragment + adapters) was collected. The DNA 
was isolated, amplified by PCR and used for cluster 
generation on the Illumina HiSeq genome analyzer. 
The 35–45 bp tags were mapped to the reference human 
genome using the Burrows-Wheeler Alignment Tool 
(BWA) or eland program allowing one mismatch. For 
each base pair in the genome, the number of overlapping 
sequence reads was determined, averaged over a 10 bp 
window and visualized in the UCSC genome browser 
(http://genome.ucsc.edu). ChIP-seq data can be 
downloaded from Gene Expression Omnibus accession 
numbers GSE46044, GSE23730, GSE30254, GSE18886 
and GSE81992.
Bioinformatic analysis
DNA binding & expression data
Raw ChIP-seq data files for AML1-ETO, 
CBFB-MYH11 and PML-RARA oncofusion proteins, 
transcription factors RUNX1 and FLI1, and acetylation 
(H3K9K14ac) profiles in Kasumi-1, ME-1 and NB4 
(GSE23730, GSE76464, GSE46044, GSE18886) cells 
were downloaded and mapped to hg19 using bwa [38]. 
Expression data sets were obtained from cohort studies 
in AML patients by Verhaak et al., 2009 (GSE6891) [21] 
and from The Cancer Genome Atlas Research Network 
(TCGA; http://cancergenome.nih.gov/) [22].
Peak extraction
Published DNA binding sites associated with 
AML1-ETO [6], CBFB-MYH11 [9] and PML-RARA 
[10] oncofusion proteins were converted to hg19 (liftOver; 
https://genome.ucsc.edu/cgi-bin/hgLiftOver).
Tag counting
Tags within a given region were counted and 
adjusted to represent the number of tags within 1Kb 
regions. Subsequently the percentage of these tags as a 
measure of the total number of tags of the sample was 
calculated and displayed as heatmaps and/or line graph.
Peak distribution
To determine genomic locations of binding sites, 
the peak files were analyzed using a script that annotates 
binding sites according to all RefSeq genes. With this 
script every binding site is annotated either as promoter 
(-500 bp to the Transcription Start Site), exon, intron or 
intergenic (everything else).
Motif analysis
For motif analysis of AML1-ETO, CBFB-
MYH11 and PML-RARA binding sites, we used 
GimmeMotifs [39].
Enrichment analysis
Pathway and gene ontology (biological process) 
enrichment analysis was performed using molecular 
signature database of Gene Set Enrichment Analysis 
(GSEA; http://software.broadinstitute.org/gsea/) [40].
Identification of potential signature genes
The expression data associated with AML subtypes 
[21, 22] was used to identify potential signature genes 
for each of the subtypes. We used microarray expression 
data [21] as our preliminary set to identify genes that 
were upregulated at a FC ≥ 8 in only one of the subtypes. 
This preliminary list of potential signature genes was 
screened against a recent cohort study [22] conducted on 
a next-generation sequencing platform. The genes passing 
both these filters successfully were marked as potential 
signatures for the associated AML subtypes.
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